Tevogen Bio Holdings Inc. (TVGN) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2025 Annual Meeting of Stockholders held on June 23, 2025. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Warren, New Jersey. As of the record date (April 30, 2025), there were 183,893,433 shares of Common Stock outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
A quorum was established with 167,360,586 shares represented. The following proposals were approved:
- Proposal 1: Election of Directors
- Jeffrey Feike: Elected with 150,304,146 votes for, 652,203 against, and 14,742 abstentions.
- Dr. Curtis Patton: Elected with 150,313,660 votes for, 647,811 against, and 9,620 abstentions.
- Both directors were elected as Class I directors for a three-year term.
- Proposal 2: Ratification of Auditors
- Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Votes: 167,188,556 for, 92,456 against, and 79,574 abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management commentary on future outlook, specific risks, contingencies, or unusual items beyond the standard disclosure of the voting process.
Investor Verification Checklist
- Verify the final certification of the election results by the inspector of elections.
- Confirm the commencement of the three-year term for the newly elected Class I directors.
- Review the Definitive Proxy Statement (Schedule 14A) filed on April 30, 2025, for detailed biographies of the elected directors.
- Monitor upcoming filings for the appointment of KPMG LLP's engagement letter and audit scope for the 2025 fiscal year.